Transcriptomics

Dataset Information

0

MEK Inhibitor Trametinib combined with RTK Inhibitor Anlotinib in KRAS-Mutant Lung Cancer


ABSTRACT: Oncogenic KRAS mutations frequently detected in non-small cell lung cancer (NSCLC) have been considered undruggable until recent development of inhibitors, e.g., sortorasib, adagrasib or divarasib, specifically targeting KRASG12C. However, it still remains as a big challenge to target all the KRAS mutants besides KRASG12C. We here found that MEK inhibitor trametinib treatment results in the feedback activation of multiple receptor tyrosine kinases (RTKs) in NSCLC, and combined treatments with trametinib and anlotinib, a pan-RTK inhibitor, effectively inhibited KRAS-mutant lung cancer progression.

ORGANISM(S): Homo sapiens

PROVIDER: GSE283634 | GEO | 2024/12/08

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-11-11 | GSE247512 | GEO
| PRJNA1039260 | ENA
2018-11-30 | E-MTAB-5997 | biostudies-arrayexpress
2019-07-01 | E-MTAB-7068 | biostudies-arrayexpress
2024-05-17 | GSE236258 | GEO
2020-11-09 | GSE142031 | GEO
2024-11-01 | GSE246804 | GEO
2023-05-12 | PXD039726 | JPOST Repository
2024-06-27 | GSE270541 | GEO
2024-05-03 | GSE255847 | GEO